Research Letter
Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems
JAMA Internal Medicine 10.1001/jamainternmed.2026.5774November 16, 2026 at 11:00 AM EST
This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.